US
US Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $190.9 Mn.
Canada at 20.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$636.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $162.2 Mn | — | — |
| 2025 (base) | $190.9 Mn | +$28.7 Mn | — |
| 2026 (forecast) | $224.7 Mn | +$33.8 Mn | +17.7% |
| 2027 (forecast) | $264.5 Mn | +$39.8 Mn | +38.5% |
| 2028 (forecast) | $311.3 Mn | +$46.8 Mn | +63.1% |
| 2029 (forecast) | $366.4 Mn | +$55.1 Mn | +91.9% |
| 2030 (forecast) | $431.2 Mn | +$64.8 Mn | +125.9% |
| 2031 (forecast) | $507.5 Mn | +$76.3 Mn | +165.9% |
| 2032 (forecast) | $597.4 Mn | +$89.8 Mn | +212.9% |
| 2033 (forecast) | $703.1 Mn | +$105.7 Mn | +268.3% |
| 2034 (forecast) | $827.5 Mn | +$124.4 Mn | +333.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$190.9 Mn
Canada
$36.6 Mn
China
$33.1 Mn
Japan
$23.5 Mn
Germany
$13.7 Mn
UK
$12.2 Mn
Brazil
$12.3 Mn
Italy
$11.7 Mn
France
$10.8 Mn
Ecuador
$9.6 Mn
India
$8.6 Mn
Spain
$8.0 Mn
Mexico
$6.6 Mn
Saudi Arabia
$6.5 Mn
Australia
$5.4 Mn
New Zealand
$5.1 Mn
Russia
$4.3 Mn
South Africa
$2.8 Mn
UAE
$2.1 Mn
Egypt
$1.3 Mn
Philippines
$1.0 Mn
Malaysia
$0.9 Mn
Hong Kong
$0.7 Mn
Thailand
$0.6 Mn
Singapore
$0.4 Mn
Kenya
$0.3 Mn
Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.
Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.
The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US
US
US
US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Digital Health · US
Medical Devices · US